Burden, Trends, and Future Projections of Multiple Myeloma in China from 1990 to 2023.

Huiwen Liu, Jiazi Zhou, Hong Liu, Depei Wu

Abstract read

In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Huiwen LiuNational Clinical Research Center for Hematologic Diseases, Jiangsu Key Laboratory of Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

Jiazi ZhouNational Clinical Research Center for Hematologic Diseases, Jiangsu Key Laboratory of Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

Hong LiuNational Clinical Research Center for Hematologic Diseases, Jiangsu Key Laboratory of Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

Depei WuNational Clinical Research Center for Hematologic Diseases, Jiangsu Key Laboratory of Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.ORCID 0000-0002-6312-3863

Funding

Jiangsu Provincial Medical Innovation Center CXZX202201National Key R&D Program of China 2022YFC2502700National Natural Science Foundation of China 82330008Priority Academic Program Development of Jiangsu Higher Education Institutions

6 · The paper itself

Abstract

backgroundMultiple myeloma (MM) is a malignant plasma cell disorder associated with substantial mortality and long-term disability. With rapid population aging in China, its disease burden may be increasing, yet comprehensive long-term assessments remain limited.

methodsUsing data from the Global Burden of Disease Study 2023, we evaluated trends in prevalence, incidence, deaths, and disability-adjusted life years (DALYs) of MM in China from 1990 to 2023. Age-standardized rates were analyzed using Joinpoint regression to estimate temporal trends.

resultsBetween 1990 and 2023, prevalence, incidence, deaths, and DALYs of MM increased markedly in China, with consistent upward trends in age-standardized rates. The burden was concentrated among older adults and was higher in males than females. Decomposition analysis showed that epidemiological changes were the primary driver of increased DALYs and deaths. Forecasting analyses suggest that although age-standardized mortality and DALY rates may gradually decline, the absolute number of deaths is expected to continue rising.

conclusionsThe burden of MM in China has increased substantially over the past three decades and is projected to remain high. Strengthening early detection, risk-oriented prevention, and long-term management strategies is essential to mitigate future disease burden.

Indexed as

DALYsdecomposition analysisepidemiological changeglobal burden of diseasemultiple myelomatrends

Identifiers

PMID42588666

DOI10.3390/cancers18152449

PMCPMC13465519

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.